XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 22.02.2024

Das Instrument EN9 SE0003943620 ENZYMATICA AB EQUITY wird ex Kapitalmassnahme gehandelt am 22.02.2024
The instrument EN9 SE0003943620 ENZYMATICA AB EQUITY is traded ex capital adjustment on 22.02.2024

Das Instrument D6Z NO0012547308 STANDARD SUPPLY NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 22.02.2024 und ex Kapitalmassnahme am 23.02.2024
The instrument D6Z NO0012547308 STANDARD SUPPLY NK -,10 EQUITY is traded cum capital adjustment on 22.02.2024 and ex capital adjustment on 23.02.2024

Das Instrument 4YD SE0005454873 NANOLOGICA AB EQUITY wird cum Kapitalmassnahme gehandelt am 22.02.2024 und ex Kapitalmassnahme am 23.02.2024
The instrument 4YD SE0005454873 NANOLOGICA AB EQUITY is traded cum capital adjustment on 22.02.2024 and ex capital adjustment on 23.02.2024

Das Instrument 7XB SE0007789409 XBRANE BIOPHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 22.02.2024 und ex Kapitalmassnahme am 23.02.2024
The instrument 7XB SE0007789409 XBRANE BIOPHARMA AB EQUITY is traded cum capital adjustment on 22.02.2024 and ex capital adjustment on 23.02.2024

Das Instrument A2S1 BMG0620W2019 ASIAN CITRUS HLDGS HD-,01 EQUITY wird ex Kapitalmassnahme gehandelt am 22.02.2024
The instrument A2S1 BMG0620W2019 ASIAN CITRUS HLDGS HD-,01 EQUITY is traded ex capital adjustment on 22.02.2024

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!

In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.

Hier klicken

Zeit	Aktuelle Nachrichten
18.04.	ASIAN CITRUS (00073): TERMINATION OF DISCLOSEABLE TRANSACTION IN RELATION TO FORMATION OF JOINT VENTURE COMPANY
27.03.	ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT
27.03.	ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT
27.03.	ASIAN CITRUS (00073): 2023/24 INTERIM REPORT
27.03.	XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 27.03.2024	The following instruments on XETRA do have their first trading 27.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 27.03.2024 Aktien 1 BMG0620W3009 Asian Citrus Holdings... ► Artikel lesen

Zeit

Aktuelle Nachrichten

18.04.

ASIAN CITRUS (00073): TERMINATION OF DISCLOSEABLE TRANSACTION IN RELATION TO FORMATION OF JOINT VENTURE COMPANY

27.03.

ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT

27.03.

ASIAN CITRUS (00073): NOTIFICATION LETTER WITH REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT

27.03.

ASIAN CITRUS (00073): 2023/24 INTERIM REPORT

27.03.

XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 27.03.2024

The following instruments on XETRA do have their first trading 27.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 27.03.2024 Aktien 1 BMG0620W3009 Asian Citrus Holdings...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Mo	ENZYMATICA AB: MDR certification was Enzymatica's highlight in Q1
Do	Enzymatica AB: Enzymatica Interim report Q1/2024: MDR certification opens up great commercial opportunities	LUND, Sweden, April 25, 2024 /PRNewswire/ -- First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic... ► Artikel lesen
09.04.	ENZYMATICA AB: Enzymatica publishes annual report for 2023
27.03.	Notice of Annual General Meeting 2024 in Enzymatica AB (publ)	The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. LUND, Sweden , March... ► Artikel lesen
27.03.	Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of Enzymatica AB	Trading in Enzymatica AB paid subscription shares is to cease. The last trading day is April 2, 2024. Short name: ENZY BTA ISIN code: SE0021626710 Orderbook ID: 325501 This information is distributed... ► Artikel lesen

Zeit

Aktuelle Nachrichten

ENZYMATICA AB: MDR certification was Enzymatica's highlight in Q1

Enzymatica AB: Enzymatica Interim report Q1/2024: MDR certification opens up great commercial opportunities

LUND, Sweden, April 25, 2024 /PRNewswire/ -- First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic...
► Artikel lesen

09.04.

ENZYMATICA AB: Enzymatica publishes annual report for 2023

27.03.

Notice of Annual General Meeting 2024 in Enzymatica AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. LUND, Sweden , March...
► Artikel lesen

27.03.

Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of Enzymatica AB

Trading in Enzymatica AB paid subscription shares is to cease. The last trading day is April 2, 2024. Short name: ENZY BTA ISIN code: SE0021626710 Orderbook ID: 325501 This information is distributed...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Fr	Nanologica AB: Interim Report Q1 2024	FINANCIAL SUMMARY • Net sales for the first quarter amounted to TSEK 5,037 (355) • The operating loss for the quarter amounted to TSEK -15,331 (-10,720). • Loss after tax for the quarter amounted to... ► Artikel lesen
05.04.	Nasdaq Stockholm AB: Delisting of paid subscription units (BTA) in Nanologica AB	Upon reqest from the issuer the paid subscription shares in Nanologica AB will be delisted . Instrument: Paid subscription units -------------------------------------- Short name: NICA BTA ... ► Artikel lesen
27.02.	Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Nanologica AB (19/24)	With effect from February 28, 2024, the subscription rights in Nasdaq will be traded on the list for Equity rights. Trading will continue up until and including March 08, 2024. Instrument: Subscription... ► Artikel lesen
22.02.	XFRA CAPITAL ADJUSTMENT INFORMATION - 22.02.2024	Das Instrument EN9 SE0003943620 ENZYMATICA AB EQUITY wird ex Kapitalmassnahme gehandelt am 22.02.2024 The instrument EN9 SE0003943620 ENZYMATICA AB EQUITY is traded ex capital adjustment on 22.02.2024Das... ► Artikel lesen
02.02.	Nanologica AB: Year-End Report 2023	FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to TSEK 75 (674) and for the full year to TSEK 1,443 (1,555) • The operating loss for the quarter amounted to TSEK -35,638 (-13,251) and... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Nanologica AB: Interim Report Q1 2024

FINANCIAL SUMMARY • Net sales for the first quarter amounted to TSEK 5,037 (355) • The operating loss for the quarter amounted to TSEK -15,331 (-10,720). • Loss after tax for the quarter amounted to...
► Artikel lesen

05.04.

Nasdaq Stockholm AB: Delisting of paid subscription units (BTA) in Nanologica AB

Upon reqest from the issuer the paid subscription shares in Nanologica AB will be delisted . Instrument: Paid subscription units -------------------------------------- Short name: NICA BTA ...
► Artikel lesen

27.02.

Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Nanologica AB (19/24)

With effect from February 28, 2024, the subscription rights in Nasdaq will be traded on the list for Equity rights. Trading will continue up until and including March 08, 2024. Instrument: Subscription...
► Artikel lesen

22.02.

XFRA CAPITAL ADJUSTMENT INFORMATION - 22.02.2024

02.02.

Nanologica AB: Year-End Report 2023

FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to TSEK 75 (674) and for the full year to TSEK 1,443 (1,555) • The operating loss for the quarter amounted to TSEK -35,638 (-13,251) and...
► Artikel lesen

Zeit	Aktuelle Nachrichten
04.04.	Standard Supply AS: Completed sale of Standard Supplier
20.03.	Standard Supply AS: Sale of Standard Supplier
07.03.	STANDARD SUPPLY AS - MINUTES FROM ANNUAL GENERAL MEETING
23.02.	Standard Supply AS: Ex. dividend NOK 2.75 today
22.02.	Standard Supply AS - Notice to the Annual General Meeting

Zeit

Aktuelle Nachrichten

04.04.

Standard Supply AS: Completed sale of Standard Supplier

20.03.

Standard Supply AS: Sale of Standard Supplier

07.03.

STANDARD SUPPLY AS - MINUTES FROM ANNUAL GENERAL MEETING

23.02.

Standard Supply AS: Ex. dividend NOK 2.75 today

22.02.

Standard Supply AS - Notice to the Annual General Meeting

Zeit	Aktuelle Nachrichten
26.03.	Nasdaq Stockholm AB: New equity right for trading, Xbrane Biopharma AB TO 1	At the request of Xbrane Biopharma AB, Xbrane Biopharma equity rights will be traded on First North Growth Market as from March 27, 2024. Security name: Xbrane Biopharma AB TO 1 ---------------------------------------- Short... ► Artikel lesen
19.03.	Nasdaq Stockholm AB: Delisting of paid subscription units in Xbrane Biopharma AB	The paid subscription units in Xbrane Biopharma AB will be delisted. Last trading day for XBRANE BTUwill be on March 20, 2024. Instrument: Paid subscription units -------------------------------------- Short... ► Artikel lesen
28.02.	Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Xbrane Biopharma AB (21/24)	With effect from February 29, 2024, the unit rightsin Nasdaq will be traded on the list for Equity rights. Trading will continue up until and including March 08, 2024. Instrument: Unit rights ... ► Artikel lesen
28.02.	Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status (20/24)	Den 26 februari 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") dess bokslutskommuniké för 2023 med information om Bolagets finansiella ställning. Den 27 februari 2024 offentliggjorde Bolaget... ► Artikel lesen
26.02.	Xbrane Biopharma AB: Xbrane Biopharma releases Year-end Report 2023	Xbrane Biopharma AB's (publ.) ("Xbrane") Year-end Report 2023, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWFOURTH QUARTER 2023*• Revenue amounted to SEK 66.9... ► Artikel lesen

Zeit

Aktuelle Nachrichten

26.03.

Nasdaq Stockholm AB: New equity right for trading, Xbrane Biopharma AB TO 1

At the request of Xbrane Biopharma AB, Xbrane Biopharma equity rights will be traded on First North Growth Market as from March 27, 2024. Security name: Xbrane Biopharma AB TO 1 ---------------------------------------- Short...
► Artikel lesen

19.03.

Nasdaq Stockholm AB: Delisting of paid subscription units in Xbrane Biopharma AB

The paid subscription units in Xbrane Biopharma AB will be delisted. Last trading day for XBRANE BTUwill be on March 20, 2024. Instrument: Paid subscription units -------------------------------------- Short...
► Artikel lesen

28.02.

Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Xbrane Biopharma AB (21/24)

With effect from February 29, 2024, the unit rightsin Nasdaq will be traded on the list for Equity rights. Trading will continue up until and including March 08, 2024. Instrument: Unit rights ...
► Artikel lesen

28.02.

Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status (20/24)

Den 26 februari 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") dess bokslutskommuniké för 2023 med information om Bolagets finansiella ställning. Den 27 februari 2024 offentliggjorde Bolaget...
► Artikel lesen

26.02.

Xbrane Biopharma AB: Xbrane Biopharma releases Year-end Report 2023

Xbrane Biopharma AB's (publ.) ("Xbrane") Year-end Report 2023, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWFOURTH QUARTER 2023*• Revenue amounted to SEK 66.9...
► Artikel lesen